Exploring Soleno Therapeutics, Inc. (SLNO) Investor Profile: Who’s Buying and Why?

Are you tracking Soleno Therapeutics, Inc. (SLNO) and wondering who's investing and why? As of April 2025, 354 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 55,759,768 shares. Institutional investors hold approximately 114.45% of the float. With the share price jumping from $38.52 on April 15, 2024, to $70.08 on April 14, 2025, marking an impressive 81.93% increase, understanding the moves of major players is crucial. Keep reading to discover which institutions are leading the pack and what's driving their investment decisions in Soleno.

Soleno Therapeutics, Inc. (SLNO) Who Invests in Soleno Therapeutics, Inc. (SLNO) and Why?

Understanding the investor profile of Soleno Therapeutics, Inc. (SLNO) provides valuable insights into the market's perception of the company and its future prospects. Investors are drawn to Soleno Therapeutics for a variety of reasons, influenced by the company's growth potential, its position in the pharmaceutical market, and prevailing investment strategies.

Key investor types in Soleno Therapeutics, Inc. (SLNO) typically include:

• Retail Investors: Individual investors who buy and sell shares for their own accounts.
• Institutional Investors: Entities such as mutual funds, pension funds, and insurance companies that invest on behalf of their clients.
• Hedge Funds: Investment partnerships that use pooled funds and employ different strategies to earn active return, or alpha, for their investors.

Several factors attract these diverse investor groups to Soleno Therapeutics, Inc. (SLNO):

• Growth Prospects: Investors are often attracted to companies with high growth potential, especially in the biotechnology and pharmaceutical sectors. Soleno's focus on developing treatments for rare diseases can present significant growth opportunities if clinical trials are successful and products are approved.
• Market Position: A company's competitive positioning within its market influences investor interest. If Soleno Therapeutics holds a unique position or has a strong pipeline of potential products, it can be more attractive to investors.

The investment strategies employed by those investing in Soleno Therapeutics, Inc. (SLNO) can vary widely:

• Long-Term Holding: Some investors adopt a long-term perspective, holding shares for an extended period based on the belief that the company's value will increase over time. This strategy is often seen among institutional investors.
• Short-Term Trading: Other investors engage in short-term trading, aiming to profit from short-term price fluctuations. This approach is common among day traders and some hedge funds.
• Value Investing: Value investors seek out companies that they believe are undervalued by the market. If Soleno Therapeutics' stock price is perceived to be lower than its intrinsic value, it may attract value investors.

To further understand Soleno Therapeutics, Inc. (SLNO), review its Mission Statement, Vision, & Core Values of Soleno Therapeutics, Inc. (SLNO).

Soleno Therapeutics, Inc. (SLNO) Institutional Ownership and Major Shareholders of Soleno Therapeutics, Inc. (SLNO)

Institutional ownership in Soleno Therapeutics, Inc. (SLNO) reflects the combined holdings of various entities, including financial institutions, mutual funds, hedge funds, and other investment firms. These institutions often manage large sums of money and can significantly influence a company's stock price and overall strategy.

As of April 2025, 354 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 55,759,768 shares. This indicates a substantial level of institutional interest in Soleno Therapeutics, Inc. (SLNO).

Here's a list of the top institutional holders of Soleno Therapeutics, Inc. (SLNO), reflecting their ownership percentages:

• Vivo Capital, LLC: 13.72%
• Janus Henderson Group Plc
• Nantahala Capital Management, LLC: 8.57%
• Adage Capital Partners Gp LLC: 6.05%
• venBio Select Advisor LLC: 5.51%
• BlackRock, Inc.: 4.38%
• Vanguard Group Inc
• Price T Rowe Associates Inc /md/
• Commodore Capital Lp
• Susquehanna International Group, Llp

These major shareholders include individual investors, mutual funds, hedge funds, and institutions. Schedule 13D filings indicate that investors hold (or held) more than 5% of the company and intend (or intended) to actively pursue a change in business strategy. Schedule 13G filings indicate a passive investment of over 5%.

Recent data indicates shifts in institutional ownership. For example, in the most recent quarter, 99 institutional investors increased their holdings in Soleno Therapeutics, Inc. (SLNO), while 40 decreased their positions.

Here is a table summarizing some of the changes in shareholdings by institutional investors, as of April 2025:

Institutional investors play a crucial role in Soleno Therapeutics, Inc. (SLNO)'s stock performance and strategic direction. Their investment decisions can drive trading volume and influence stock valuation. Increased institutional ownership often provides stability and confidence in the company's prospects, while decreased ownership may signal concerns or shifts in investment strategy.

To gain further insights into Soleno Therapeutics, Inc. (SLNO)'s mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Soleno Therapeutics, Inc. (SLNO).

Soleno Therapeutics, Inc. (SLNO) Key Investors and Their Impact on Soleno Therapeutics, Inc. (SLNO)

Understanding the investor profile of Soleno Therapeutics, Inc. (SLNO) provides valuable insights into the company's stability, growth potential, and market sentiment. Examining who is investing and their recent activities can offer a glimpse into the perceived value and future prospects of Soleno Therapeutics, Inc. (SLNO). Here’s an overview of notable investors and their potential influence.

While specific, real-time details on all investors and their precise impact can fluctuate, here are general observations based on available information and common investment dynamics:

• Institutional Investors: These entities, such as mutual funds, hedge funds, and pension funds, often hold significant stakes in publicly traded companies. Their investment decisions are typically driven by in-depth research and analysis. A strong presence of institutional investors can lend credibility to Soleno Therapeutics, Inc. (SLNO).
• Individual Investors: These investors can range from retail traders to high-net-worth individuals. Their collective sentiment can drive short-term stock movements, especially in response to news or market trends.
• Activist Investors: These investors purchase significant stakes with the goal of influencing company management and strategy. Their involvement can lead to major changes in corporate policy, operations, or even strategic direction.
• Strategic Investors: These may include other companies in the pharmaceutical or biotechnology sectors. Their investment can signal potential collaborations, partnerships, or even future acquisition possibilities.

Key investors can exert considerable influence on Soleno Therapeutics, Inc. (SLNO) through several mechanisms:

• Voting Rights: Large shareholders have a greater say in company decisions, including the election of board members and approval of major transactions.
• Market Sentiment: Significant investments or divestments by prominent investors can impact market confidence, driving stock prices up or down.
• Strategic Guidance: Experienced investors may offer valuable insights and guidance to company management, helping to shape strategic decisions.
• Access to Capital: Strong investor backing can facilitate access to additional funding through equity or debt offerings.

Keeping track of recent moves by key investors provides crucial insights. Examples of such moves include:

• Significant stake purchases: Indicate strong confidence in the company's future prospects.
• Large-scale selling: May signal concerns about the company's performance or market conditions.
• Activist campaigns: Can lead to significant changes in company strategy or management.
• Increased or decreased positions: Can reflect evolving investor sentiment based on company performance, clinical trial results, or market dynamics.

For more detailed information on Soleno Therapeutics, Inc. (SLNO), you can explore: Soleno Therapeutics, Inc. (SLNO): History, Ownership, Mission, How It Works & Makes Money

Soleno Therapeutics, Inc. (SLNO) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Soleno Therapeutics, Inc. (SLNO) can provide valuable insights for current and potential shareholders. Examining major shareholder activity, recent market behavior, and analyst perspectives helps paint a comprehensive picture of the company's perceived value and future prospects.

Soleno Therapeutics, Inc. (SLNO) has garnered attention from various institutional investors. Analyzing their trading activity offers clues about the prevailing sentiment surrounding the stock. Significant purchases may indicate confidence in the company's growth potential, while increased selling could signal concerns about future performance. Keeping tabs on these movements is crucial for gauging overall investor confidence.

The stock market's reaction to shifts in ownership or substantial investor actions can be telling. For instance, a large institutional investor acquiring a significant stake might lead to a surge in stock price, reflecting positive market sentiment. Conversely, a major sell-off could trigger a price decline. Monitoring these reactions helps investors understand how the market interprets specific events related to Soleno Therapeutics, Inc. (SLNO).

Analyst perspectives play a key role in shaping investor sentiment. Analysts often provide insights on how key investors might influence Soleno Therapeutics, Inc. (SLNO)'s future. These analyses can cover various aspects, including the potential impact of large investments on the company's strategic direction, research and development efforts, and overall financial health. Investors often look to these expert opinions to validate their investment decisions.

To further illustrate the dynamics of investor sentiment and market impact, consider the following points:

• Institutional Ownership: Tracking the percentage of shares held by institutions provides a general sense of market confidence.
• Trading Volume: Monitoring trading volume around significant investor events can highlight the intensity of market reactions.
• Analyst Ratings: Keeping an eye on analyst ratings and price targets offers insights into professional expectations for the stock.

For example, if a well-regarded analyst upgrades Soleno Therapeutics, Inc. (SLNO) based on positive clinical trial data and a major investor increases their holdings, this could lead to a significant boost in market confidence and stock valuation. Conversely, negative clinical trial results coupled with a large investor reducing their position might result in a negative market reaction.

Here's a look at potential factors influencing investor sentiment:

• Clinical Trial Outcomes: Positive results from clinical trials typically boost investor confidence.
• Regulatory Approvals: Approvals from regulatory bodies like the FDA can significantly impact the stock price.
• Financial Performance: Strong financial results, such as increased revenue or reduced losses, can attract more investors.

Changes in investor ownership can signal shifts in market perception. For instance, a notable increase in institutional ownership might suggest growing confidence in the company's long-term prospects, whereas a decrease could indicate concerns about its future performance. These shifts often correlate with strategic decisions made by major investors, reflecting their evolving outlook on Soleno Therapeutics, Inc. (SLNO).

For further insights into the company's financial standing, explore Breaking Down Soleno Therapeutics, Inc. (SLNO) Financial Health: Key Insights for Investors.